Heart failure is the leading contributor of human morbidity and mortality in the developed world 1 . Although a number of risk factors have been recognized for heart failure, the molecular mechanisms contributing to the initiation of heart failure are incompletely understood 2 . Recent studies have demonstrated that heart failure can be prevented or reverted, at least in experimental models, by caloric restriction, a dietary regimen that limits calorie intake [3] [4] [5] .
a r t i c l e s
Heart failure is the leading contributor of human morbidity and mortality in the developed world 1 . Although a number of risk factors have been recognized for heart failure, the molecular mechanisms contributing to the initiation of heart failure are incompletely understood 2 . Recent studies have demonstrated that heart failure can be prevented or reverted, at least in experimental models, by caloric restriction, a dietary regimen that limits calorie intake [3] [4] [5] .
The health benefits of calorie restriction are thought to be mediated by a family of NAD-dependent deacetylases called sirtuins. The mammalian genome encodes seven ubiquitously expressed sirtuin isoforms (SIRT1-SIRT7), which are emerging as key regulators of a myriad of biological functions, ranging from cell growth to lifespan extension 6 . Among the sirtuins, SIRT6, a chromatin-associated deacetylase, is considered to have a leading role in regulating genomic stability, cellular metabolism, stress response and aging [7] [8] [9] [10] [11] [12] . SIRT6 deacetylates H3K9 and acts as a transcriptional co-repressor of NF-κB and hypoxia inducible factor-1α (HIF-1α) target genes in a tissue-and context-dependent manner 8, 10, 13 . SIRT6-deficient mice show severe hypoglycemia and a multisystemic accelerated aging phenotype and die at around 26 d after birth 12 . The hypoglycemia of SIRT6-deficient mice seems to result from increased activity of HIF-1α target genes and increased glucose uptake by multiple organs 13, 14 . However, neither correction of hypoglycemia by feeding mice with glucose nor reduced NF-κB signaling could completely rescue the lethality of SIRT6-deficient mice, suggesting that additional mechanisms must contribute to the mutant phenotype of SIRT6-deficient mice 8, 14 .
Mammalian aging and aging-associated diseases have been shown to be associated with dysregulation of IGF-Akt signaling 15 . In the heart, although short-term activation of IGF-Akt signaling promotes physiologic growth, sustained hyperactivation leads to the development of pathologic hypertrophy and heart failure 16, 17 . Although much is known about the positive activators of this pathway, very little is known about the endogenous negative regulators, which might have potential to block the IGF-Akt pathway and protect the heart from developing heart failure.
In this study, we show that SIRT6 directly controls IGF-Akt signaling at the level of chromatin through c-Jun, a stress-responsive transcription factor, and deacetylation of H3K9. Our findings also demonstrate that SIRT6 deficiency induces hyperactivation of IGF-Akt signaling, which culminates in the development of cardiac hypertrophy and heart failure in mice.
RESULTS

Loss of SIRT6 induces cardiac hypertrophy and failure
To study the role of SIRT6 in the development of heart failure, we first analyzed SIRT6 expression in failing human hearts and in mouse hearts in which we had induced hypertrophy by either surgically creating transverse aortic constriction (TAC) or infusing the hypertrophic agonists a r t i c l e s 1 6 4 4 VOLUME 18 | NUMBER 11 | NOVEMBER 2012 nature medicine isoproterenol (ISO) or angiotensin-II (Ang-II). In both human and mouse hearts, SIRT6 amounts were markedly reduced compared to control hearts (Fig. 1a,b and Supplementary Table 1 ), suggesting that SIRT6 deficiency is associated with the development of cardiac hypertrophy and failure. To test whether SIRT6 deficiency contributes to heart disease, we analyzed hearts of SIRT6 whole-body knockout mice. SIRT6 knockout mice on an inbred genetic (129sv) background die at around 26 d of age 12 , whereas SIRT6 knockout mice on crossbred genetic backgrounds survive for up to 1 year 14 . We therefore analyzed crossbred SIRT6 knockout mice(129sv/C57BL6) for this study. These crossbred SIRT6 knockout mice spontaneously developed concentric cardiac hypertrophy at around 8-12 weeks of age with a significantly increased heart weight to body weight (HW/BW) ratio, reduced left ventricular internal diameter and reduced fractional shortening ( Fig. 1c-e) . SIRT6 knockout hearts also showed increased expression of cardiac fetal genes, increased cardiomyocyte size and interstitial fibrosis (Fig. 1f,g ). These hearts also showed severe degenerative changes, including aggregation and vacuolization of mitochondria (Fig. 1g) . SIRT6 knockout hearts also expressed higher levels of agingassociated cytoskeleton proteins 18 such as actin, actinin and tubulin; fibrotic markers such as α-smooth muscle actin, myosin, collagen-1 and fibronectin; and apoptotic markers such as caspase 3, Bax, TRAIL, Bim, FasL and p27 (Fig. 1h,i) , which are signs of a failing heart. To test whether a partial reduction in SIRT6 expression, as seen in human failing hearts (Supplementary Fig. 1a) , could be sufficient to induce heart failure, we analyzed the hearts of SIRT6 +/− heterozygous mice. Young SIRT6 +/− mice showed no noticeable cardiac defects; however, at around 6 months of age, they spontaneously developed characteristics of pathologic cardiac hypertrophy, such as increased HW/BW and heart weight to tibia length (HW/TL) ratios, increased cardiomyocyte size and interstitial fibrosis ( Supplementary  Fig. 1b-d) , suggesting that reduced expression of SIRT6 can contribute to the development of cardiac hypertrophy.
To study the cardiac-specific effects of SIRT6, we used a tamoxifeninducible α-myosin heavy chain (α-MHC)-Cre system to delete SIRT6 in the hearts of adult mice (Supplementary Fig. 2 ). Cardiac-specific deletion of SIRT6 resulted in a significantly increased HW/TL ratio, increased left ventricular wall thickness, increased cardiomyocyte cross-sectional area and induction of interstitial fibrosis (Fig. 2a-c) . Echocardiography of these mice revealed significantly reduced cardiac contractile function (Fig. 2d) . In addition, cardiac-specific SIRT6-deleted hearts had increased expression of fetal genes and cell death markers (Fig. 2e,f) . We obtained similar results by analyzing hearts of mice in which SIRT6 was deleted both in the skeletal and cardiac muscles by use of the MCK-Cre system (N.R.S., D.B.L. and M.P.G., unpublished data). These data demonstrate that SIRT6 is an endogenous negative regulator of cardiac hypertrophy.
SIRT6 activation blocks development of cardiac hypertrophy
We first examined the effect of SIRT6 overexpression in an in vitro model of cardiomyocyte hypertrophy. We infected neonatal rat cardiomyocytes with either a control vector or a vector expressing SIRT6 (Supplementary Fig. 3a,b) . SIRT6-overexpressing cells had a dampened hypertrophic response to phenylephrine treatment based on analysis of protein synthesis, atrial natriuretic factor (ANF) release from nuclei and sarcomere organization, which are hallmarks of cardiomyocyte hypertrophy (Fig. 3a,b) . These results indicate an antihypertrophic effect of SIRT6 in cardiomyocytes. To evaluate the antihypertrophic effects of SIRT6 in vivo, we generated cardiac-specific SIRT6 transgenic mice (Supplementary Fig. 3c ). At baseline, SIRT6 transgenic mice had no noticeable cardiac abnormalities. We induced cardiac hypertrophy in these mice by either surgically creating TAC or infusing ISO into the abdomen. Nontransgenic mice subjected to TAC for 4 weeks developed massive cardiac hypertrophy, as indicated by an increased HW/TL ratio, increased left ventricular wall thickness and decreased fractional shortening ( Fig. 3c-e) . These changes were accompanied by an increased cardiomyocyte cross-sectional area and induction of fibrosis (Fig. 3f,g) . Notably, the hearts of SIRT6 transgenic mice did not undergo similar pathological growth after being subjected to TAC (Fig. 3c-g ). We found similar cardioprotective effects of SIRT6 overexpression in the ISO model of cardiac hypertrophy ( Supplementary  Fig. 3d-g ). These data indicate that SIRT6 overexpression is capable of blocking the development of pathologic cardiac hypertrophy.
SIRT6 antagonizes IGF signaling SIRT6 knockout mice on the 129Sv genetic background develop severe hypoglycemia and hypoinsulinemia, which is mediated through alterations in HIF-1α activity 13, 14 . To test whether such metabolic changes contribute to the cardiac phenotype we observed a r t i c l e s in SIRT6-deficient mice, we analyzed myocardial glucose uptake, serum insulin and blood glucose concentrations and the expression of HIF-1α target glycolytic genes, previously shown to be regulated by SIRT6. We found no change in glucose uptake in the hearts of SIRT6 knockout mice (Supplementary Fig. 4a ). We also noted no statistically significant variation in blood glucose or insulin concentrations in these mice ( Supplementary Fig. 4b,c) . Western blot analysis revealed that expression of the HIF-1α target genes PFK1, TPI1 and GAPDH were unchanged in SIRT6 knockout hearts ( Supplementary  Fig. 4d ). In addition, we found no noticeable changes in the expression of mitochondrial superoxide dismutase 2 (MnSOD) and glutathione S-transferase (GST), which have previously been shown to be targeted by the transcription factor NF-κB ( Supplementary  Fig. 4d ). These findings indicate that the development of heart failure in SIRT6 knockout mice is not mediated by alterations in either systemic glucose homeostasis or activation of HIF-1α or NF-κB signaling in the heart. We next tested whether effects on IGF-Akt signaling might underlie the cardiac phenotype of SIRT6 knockout mice. SIRT6 knockout hearts had substantially increased amounts of proteins (and/or phosphoproteins) related to this pathway, including IGF1 receptor (IGF1R), insulin receptor (InsR), extracellular signal-regulated kinase 1 (ERK1)/ERK2, Akt, forkhead box O1 (Foxo1), glycogen synthase kinase 3 (GSK3) and IGF2 (Fig. 4a and Supplementary Fig. 4e ). The amount of membrane-bound IGF2 was also increased in SIRT6 knockout hearts (Supplementary Fig. 4f ). We also noted that failing human hearts had higher amounts of IGF1R and phosphorylated Akt expression compared to controls; similarly, hypertrophic mouse hearts in the TAC and ISO models had increased expression of these proteins compared to control hearts ( Supplementary Fig. 4g,h) . Additionally, SIRT6 knockout hearts showed increased expression of transcription and translation factors acting downstream of IGF signaling, including Myc, β-catenin, eukaryotic translation initiation factor 4E (eIF4E), S6P and p70S6K (Fig. 4b) . However, SIRT6 knockout hearts did not show increased expression of p38 or tropomyosin, which served as loading controls (Fig. 4a,b) . Conversely, the expression and phosphorylation of IGF signaling-related proteins were attenuated in SIRT6-overexpressing transgenic hearts (Supplementary Fig. 5a ). These data indicate that induction of cardiac hypertrophy in SIRT6-deficient hearts might be related to hyperactivation of IGF-Akt signaling-related proteins.
Because SIRT6-deficient mice develop a multiorgan aging phenotype, we asked whether the effect of SIRT6 on IGF signaling is limited to the heart or is a more widespread phenomenon. We first analyzed the effects of nicotinamide (NAM), a general inhibitor of sirtuins, and trichostatin A (TSA), a class I and II histone deacetylase (HDAC) inhibitor. Treatment with NAM, but not TSA, increased the expression and phosphorylation of IGF1R in three different cells (adult mouse cardiac fibroblasts and 3T3L and Cos7 cells) analyzed, indicative of the involvement of a sirtuin in IGF1R activation (Supplementary Fig. 5b ). We next analyzed the effects of SIRT6 deficiency in mouse embryonic fibroblasts (MEFs). As in the heart, SIRT6 knockout MEFs showed hyperactivation of IGF signaling-related proteins (Supplementary Fig. 5c ). SIRT6 knockdown in 293T cells using retroviral vectors targeting SIRT6 had a similar effect (Supplementary Fig. 5d ). To confirm these findings, we performed a reconstitution experiment in which we re-expressed SIRT6 in SIRT6 knockout cells. Re-expression of wild-type SIRT6, but not a SIRT6 mutant lacking deacetylase activity, attenuated IGF1R activation in SIRT6 knockout MEFs (Supplementary Fig. 5e ), indicating that SIRT6-dependent regulation of IGF signaling is not limited to the heart. We also tested whether deficiency of other sirtuins present in the nucleus, such as SIRT1, can activate IGF1R. However, IGF1R activation occurred in SIRT6 knockout but not in SIRT1 knockout hearts (Fig. 4c) . We have recently shown that Akt membrane localization and activation are under the control of SIRT1 (ref. 19) . SIRT6 knockout hearts, in which Akt was activated, showed markedly increased expression of SIRT1 (Fig. 4c) , which might be needed for mediating Akt activation in these hearts. Taken together, these findings indicate that SIRT6 has a central role in regulating IGF-Akt signaling. 
SIRT6 blocks IGF signaling by deacetylating H3K9
Because SIRT6 is a chromatin-associated deacetylase, we posited that it could directly influence the expression of IGF signaling-related genes by modifying chromatin. To test this hypothesis, we used available microarray data from the skeletal muscle of SIRT6 knockout mice 13 . The results of a clustering analysis using these data suggested that SIRT6 deficiency substantially increased the expression of key IGF signaling-related genes, including Igf2, Igf2r, Foxo1, Igf1r, Mapk3, Pten, Gsk3, Irs2, Akt3 and Ins2 (Supplementary Fig. 6a) , whereas the expression of other such genes, including Ins1 and Igf1, was down regulated (Supplementary Fig. 6b ). To test whether similar changes also take place in the heart, we performed real-time PCR. In SIRT6 knockout hearts, the mRNA levels of key IGF signaling-related genes, including Igf1r, Igf2r, Insr, Irs2, Akt1, Akt3, Igf2, Mapk3, Ins2, Igfbp3, Pten, Gsk3b, Foxo1 and Mtor, were significantly upregulated, whereas Igf1 was downregulated (Fig. 4d) . The expression of Akt2, an IGF signaling-related gene, and At1 and At4, which are unrelated to IGF signaling, were unchanged (Fig. 4d) , indicating that SIRT6 deficiency specifically induces certain IGF signaling genes rather than nonspecifically activating the cellular transcription machinery. By chromatin immunoprecipitation (ChIP), we found that SIRT6 binds to promoters of IGF signaling-related genes in cardiomyocytes, and knockdown of SIRT6 reduced its binding to these promoters ( Fig. 4e and Supplementary Fig. 6c ), indicating the specificity of SIRT6 binding to these genes. SIRT6 deacetylates H3K9 and thereby regulates gene expression by modifying chromatin structure 10 . We therefore asked whether SIRT6 deficiency results in increased H3K9 acetylation in the promoters of upregulated IGF signaling-related genes. ChIP analysis revealed increased acetylation of H3K9 in SIRT6-deficient cells compared to wild-type control cells (Fig. 5a and Supplementary Fig. 7a ). However, acetylation of H3K14 was not increased, which served as a negative control (Supplementary Fig. 7b,c ). These data demonstrate that SIRT6 directly suppresses the expression of key IGF signaling-related genes by deacetylating H3K9 at their promoters.
SIRT6 suppresses the transcriptional activity of c-Jun
To search for a transcription factor that could be targeted by SIRT6 and that might regulate the expression of IGF signaling-related genes, we performed an in silico analysis and identified an evolutionarily conserved c-Jun binding site in the promoters of IGF signaling-related genes (Supplementary Fig. 8 ). c-Jun is a stressresponsive subunit of the AP-1 transcription factor 20 . Supporting the potential role of c-Jun in SIRT6 function, we found marked changes in the expression levels of well-known AP-1 target genes in SIRT6 knockout skeletal muscle based on the available microarray data 13 ( Supplementary Fig. 9a ). We found that SIRT6 was bound to AP-1 target genes by ChIP analysis (Supplementary Fig. 9 b) and that SIRT6 physically interacts with c-Jun in cardiomyocytes ( Fig. 5b and  Supplementary Fig. 10a) , consistent with the idea that SIRT6 is a regulator of c-Jun-dependent gene transcription. We next tested the effect of SIRT6 on the transcriptional activity of c-Jun, as assessed by a luciferase reporter assay using a reporter construct carrying multiple c-Jun binding sites. This assay indicated that SIRT6 knockdown npg a r t i c l e s enhanced the transcriptional activity of endogenous c-Jun ( Fig. 5c and Supplementary Fig. 10b ). Moreover, wild-type SIRT6, but not a catalytic mutant (H133Y SIRT6), attenuated the transcriptional activity of c-Jun ( Fig. 5d and Supplementary Fig. 10c ), suggesting that the deacetylase activity of SIRT6 is needed for attenuating c-Jun-dependent gene transcription. As assessed by ChIP analysis using a c-Jun-specific antibody, c-Jun was bound to the promoters of IGF signaling-related genes and loss of SIRT6 enhanced the binding of c-Jun to target promoters ( Fig. 5e and Supplementary  Fig. 10d,e) , indicating that the enhanced transcriptional activity of c-Jun in SIRT6-deficient cells contributes to the increased expression of IGF signaling-related genes. We next asked whether loss of c-Jun affects the occupancy of SIRT6 at promoters of IGF signaling-related genes. Knockdown of c-Jun significantly reduced SIRT6 occupancy at these promoters (Fig. 5f,g  and Supplementary Fig. 10f ), indicating that SIRT6 is specifically recruited to these promoters by forming a complex with c-Jun.
Inhibition of c-Jun or IGF-Akt signaling blocks cardiac hypertrophy
Having shown that SIRT6 deficiency activates c-Jun-dependent transcription, we next asked whether inhibition of c-Jun could block the hypertrophy of SIRT6-deficient cardiomyocytes. Inhibition of c-Jun in SIRT6 knockout MEFs by treating them with an AP-1-specific inhibitor, tanshinone IIa (Tan-IIa) 21 , for 24 h led to decreased expression and phosphorylation of IGF1R in a concentration-dependent manner (Fig. 6a) . The compound did not have this effect in wildtype cells (Fig. 6a) . We next inhibited c-Jun function using an adenovirus expressing a dominant-negative version of c-Jun, which, when infected into cardiomyocytes, blocked the activity of endogenous c-Jun (Supplementary Fig. 11a) . The hypertrophic response of SIRT6-deficient cardiomyocytes, as measured by [ 3 H]-leucine incorporation into total cellular protein, expression of ANF and sarcomere reorganization, was completely blocked by c-Jun inhibition (Fig. 6b,c and Supplementary Fig. 11b,c) . These effects were associated with reduced phosphorylation of IGF1R and reduced mRNA expression of key IGF signaling-related genes, such as Igf2, Igf1r and Irs2 (Supplementary Fig. 11d,e) , suggesting that the hypertrophy of SIRT6-deficient cardiomyocytes can be attributed to the increased transcriptional activity of c-Jun. Confirming these findings, we found that Tan-IIa treatment also blocked the hypertrophic response of SIRT6-deficient cardiomyocytes (Supplementary Fig. 12a,b) . Administration of Tan-IIa to SIRT6 knockout mice blocked the cardiac hypertrophic response in vivo (Fig. 6d,e and Supplementary  Fig. 13a-c) , and this effect was associated with inhibition of Igf2 and fetal gene expression (Supplementary Fig. 13d ). These data demonstrate that SIRT6 deficiency induces cardiac hypertrophy through hyperactivation of c-Jun.
To obtain evidence that cardiac hypertrophy of SIRT6-deficient cells results from c-Jun-dependent hyperactivation of IGF-Akt signaling, we performed a series of rescue experiments using specific inhibitors of IGF-Akt signaling. Treatment of SIRT6-deficient cardiomyocytes with PQ401, a pharmacological inhibitor of IGF signaling, significantly (P < 0.001) blocked hypertrophy of cardiomyocytes (sarcomeric reorganization, ANF release, protein synthesis and NFAT (nuclear factor of activated T cells) promoter activity) (Supplementary Fig. 12b-e) . Knockdown of IGF1R expression using siRNA had similar effects (Supplementary Fig. 14a-e) . An Akt inhibitor, Akt-v (triciribine) 19 , also blocked the hypertrophic response of SIRT6-deficient cardiomyocytes ( Supplementary  Fig. 12b,d-f) . To test whether inhibition of IGF signaling could block the cardiac hypertrophy of SIRT6 knockout mice in vivo, we treated these mice with PQ401 for 14 d. PQ401 treatment of SIRT6 knockout mice prevented the increase in the HW/TL ratio and the crosssectional area of cardiomyocytes, with significant improvement in contractile function, which was associated with reduced activation of IGF-Akt signaling (Fig. 6d,e and Supplementary Fig. 15a-c) .
Treatment of cardiac-specific SIRT6-deleted mice with PQ401 had similar effects (Fig. 6f and Supplementary 15d,e) . From these studies, we conclude that hyperactivation of IGF-Akt signaling contributes to the development of cardiac hypertrophy and heart failure in SIRT6-deficient mice.
DISCUSSION
In this study, we identify a direct link between two evolutionarily conserved nutrient-sensitive signaling pathways, the insulin/IGF and sirtuin pathways, which are widely implicated in pathophysiological conditions. Our data show that IGF signaling-related genes are negatively regulated by SIRT6 at the level of chromatin. SIRT6 deficiency enhanced H3K9 acetylation and augmented the promoter binding and transcriptional activity of c-Jun, which resulted in hyperactivation of multiple IGF signaling-related genes and the development of cardiac hypertrophy and failure. Hyperactivation of signaling by insulin and the IGF family of growth factors has been implicated in the pathophysiology of many diseases, including cancer 22 , diabetes 23 , obesity 23 , musculoskeletal disease 24 and neurodegenerative disease 25 . Dysregulation of insulin/ IGF signaling has been also reported in human end-stage failing hearts 26 . In SIRT6-deficient hearts, most of the key components of insulin/IGF signaling pathways, including IGF1R, InsR, IGF2R, IGF2, IRS2, MAPK3 and Akt, were overexpressed, but IGF1 was not. In fact, IGF1 expression was downregulated in SIRT6 knockout hearts, consistent with previous reports in which low circulating IGF1 concentrations were found in SIRT6 knockout mice [12] [13] [14] . We also found increased amounts of membrane-bound IGF2 in SIRT6 knockout hearts, suggesting that membrane-associated IGF2 might drive constant IGF signaling, contributing to the development of cardiac hypertrophy, despite low cardiac expression of IGF1. IGF2 acts on multiple receptors, including, IGF1R, IGF2R and InsR, to promote the development of pathologic cardiac hypertrophy and tumorigenesis 27, 28 . Consistent with our data, transgenic mice overexpressing IGF2 have cardiac structural changes that reflect heart failure 29 . We found that PTEN mRNA, a suppressor of IGF signaling, was modestly upregulated in SIRT6 knockout cardiomyocytes, raising the question of why increased PTEN expression was unable to block hyperactive IGF signaling in SIRT6 knockout hearts. From these studies, we deduce that SIRT6 has a major role in regulating the expression of IGF signaling-related genes and that dysregulation of this pathway might contribute to the pathophysiology of several diseases, including heart failure.
Mechanistically, SIRT6 blocks the expression of IGF signalingrelated genes through its ability to suppress the transcriptional activity of c-Jun (Fig. 6g) . c-Jun is a subunit of the transcription factor AP-1, which regulates cell proliferation, differentiation and apoptosis 20 . c-Jun is involved in the development of the embryonic heart 30 , whereas in the adult heart, c-Jun activation leads to hypertrophy and subsequent failure [31] [32] [33] [34] [35] [36] . Transgenic mice with whole-body c-Jun overexpression develop tumors of multiple organs leading to death of the mice 29 . Elevated expression of c-Jun has also been reported during aging 37 . Growth factors and oxidative stress promote the transcriptional activity of c-Jun, whereas dietary restriction antagonizes it 37, 38 . In our in silico analysis, we found evolutionarily conserved c-Jun binding sites in several insulin/IGF signaling-related gene promoters, suggesting that these genes are probably regulated by a c-Jun-dependent transcription mechanism. Consistent with this, a previous report has shown that c-Jun has a crucial role in the regulation of Igf2 expression 6 . In addition to IGF signaling-related genes, it is also possible that other c-Jun targets participate in the development of pathologic cardiac hypertrophy in SIRT6 knockout mice. In particular, as we found increased expression of many proapoptotic and prohypertrophic genes in SIRT6 knockout hearts (Trail, Bim, P27, Myc and Ctnnb1 (β-catenin)), a role of these factors in the cardiac hypertrophy of these mice cannot be excluded. However, inhibition of IGF signaling was sufficient to block the cardiac hypertrophic response in SIRT6 knockout mice, suggesting that IGF signaling has a major role in this response. Notably, we did not find upregulation of previously identified HIF-1α-targeted glycolytic genes, suggesting that SIRT6 deficiency-induced cardiac failure is not mediated through HIF-1α.
The expression of IGF2 is also regulated by genomic imprinting 28 . In the present study, two different findings argue against the loss of genomic imprinting as the cause of Igf2 activation in SIRT6 knockout cells. First, other genes that were upregulated in SIRT6 knockout cells, such as Igf1r, Akt, Gsk3 and Mapk3, are not controlled by genomic imprinting. Second, IGF2 activation was blocked by inhibiting c-Jun. Thus, it seems that activation of c-Jun is the mechanism responsible for SIRT6-mediated activation of IGF signaling-related genes and the development of cardiac hypertrophy.
In many previous studies, lifespan extension in response to caloric restriction has been linked with the activation of sirtuins and a reduction in IGF-Akt signaling 4, 6 . Among the seven members of the sirtuin family, SIRT1, SIRT3 and SIRT6 have been shown to be activated in response to caloric restriction [39] [40] [41] . However, recent studies have shown that SIRT1 deacetylates and activates Akt and thereby promotes cardiac hypertrophy and tumorigenesis in mice 42 , casting doubt on the idea that SIRT1 promotes longevity. The activation of SIRT3 has been linked to an extension of lifespan in humans 28 . Although, the underlying mechanism of the antiaging effect of SIRT3 is not known, growing evidence suggests that SIRT3 might promote longevity by facilitating mitochondrial function 42 and blocking cellular oxidative stress 43 . Our data show that the SIRT6 sirtuin directly controls IGFAkt signaling, supporting the idea that SIRT6 is capable of promoting longevity. Consistent with our findings, it was recently reported that SIRT6-overexpressing transgenic male mice that had an extended lifespan had reduced IGF signaling 44 . From these studies, it can be concluded that SIRT6 has an important role in controlling pro-growth and pro-aging IGF-Akt signaling in mammals.
Other HDACs, particularly class II HDACs, are capable of blocking the cardiac hypertrophic response. These HDACs function by shuttling in and out of the nucleus as needed to protect the heart from hypertrophic stimuli 45 . This mechanism does not apply to the negative regulatory effects of SIRT6, as we found no evidence of SIRT6 export from the nucleus during the hypertrophy of cardiomyocytes. Instead, SIRT6 levels were substantially reduced in failing human and mouse hearts in which IGF-Akt signaling was hyperactivated, suggesting that loss of SIRT6 contributes to the development of heart failure. This finding raises the possibility that low levels of SIRT6 expression might be a risk factor for heart failure in humans. In summary, this study demonstrates that the nuclear sirtuin SIRT6 directly npg a r t i c l e s controls the expression of insulin/IGF-Akt signaling-related genes at the level of chromatin and, hence, the development of cardiac hypertrophy and heart failure.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary information is available in the online version of the paper.
